Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Adult
Age Factors
Biomarkers
/ blood
Bromocriptine
/ therapeutic use
Cardiovascular Diseases
/ blood
Case-Control Studies
Dopamine Agonists
/ therapeutic use
Dyslipidemias
/ blood
Female
Fenofibrate
/ therapeutic use
Humans
Hyperprolactinemia
/ blood
Hypolipidemic Agents
/ therapeutic use
Lipids
/ blood
Middle Aged
Prolactin
/ blood
Risk Factors
Sex Factors
Time Factors
Treatment Outcome
Young Adult
Atherogenic dyslipidemia
Fibrates
Hyperprolactinemia
Risk factors
Journal
Pharmacological reports : PR
ISSN: 2299-5684
Titre abrégé: Pharmacol Rep
Pays: Switzerland
ID NLM: 101234999
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
02
05
2018
revised:
31
07
2018
accepted:
05
09
2018
pubmed:
24
11
2018
medline:
4
4
2019
entrez:
24
11
2018
Statut:
ppublish
Résumé
Elevated prolactin levels are associated with increased cardiometabolic risk. No previous study has compared the effect of hypolipidemic therapy on plasma levels of lipids and other cardiometabolic risk factors in patients with and without hyperprolactinemia. The study included three age-, weight-, blood pressure- and lipid-matched groups of premenopausal women: 18 women with untreated hyperprolactinemia, 19 women with bromocriptine-treated hyperprolactinemia and 20 drug-naïve women with normal prolactin levels. Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks. Plasma lipids, glucose homeostasis markers, as well as plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine and fibrinogen were assessed at baseline and at the end of hypolipidemic treatment. Unlike similar baseline lipid levels, plasma concentrations of the remaining investigated cardiometabolic risk factors were higher in women with elevated prolactin levels than in patients with normal prolactin levels. The impact of fenofibrate on total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels, as well as on uric acid, hsCRP, homocysteine, and fibrinogen was less pronounced in women with untreated hyperprolactinemia than in women with bromocriptine-treated hyperprolactinemia and drug-naïve women with normal prolactin levels. The results of our study indicate that cardiometabolic effects of fenofibrate depend on plasma prolactin levels.
Sections du résumé
BACKGROUND
BACKGROUND
Elevated prolactin levels are associated with increased cardiometabolic risk. No previous study has compared the effect of hypolipidemic therapy on plasma levels of lipids and other cardiometabolic risk factors in patients with and without hyperprolactinemia.
METHODS
METHODS
The study included three age-, weight-, blood pressure- and lipid-matched groups of premenopausal women: 18 women with untreated hyperprolactinemia, 19 women with bromocriptine-treated hyperprolactinemia and 20 drug-naïve women with normal prolactin levels. Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks. Plasma lipids, glucose homeostasis markers, as well as plasma levels of uric acid, high-sensitivity C-reactive protein (hsCRP), homocysteine and fibrinogen were assessed at baseline and at the end of hypolipidemic treatment.
RESULTS
RESULTS
Unlike similar baseline lipid levels, plasma concentrations of the remaining investigated cardiometabolic risk factors were higher in women with elevated prolactin levels than in patients with normal prolactin levels. The impact of fenofibrate on total cholesterol, LDL cholesterol, HDL cholesterol and triglyceride levels, as well as on uric acid, hsCRP, homocysteine, and fibrinogen was less pronounced in women with untreated hyperprolactinemia than in women with bromocriptine-treated hyperprolactinemia and drug-naïve women with normal prolactin levels.
CONCLUSIONS
CONCLUSIONS
The results of our study indicate that cardiometabolic effects of fenofibrate depend on plasma prolactin levels.
Identifiants
pubmed: 30469130
pii: S1734-1140(18)30258-5
doi: 10.1016/j.pharep.2018.09.004
pii:
doi:
Substances chimiques
Biomarkers
0
Dopamine Agonists
0
Hypolipidemic Agents
0
Lipids
0
Bromocriptine
3A64E3G5ZO
Prolactin
9002-62-4
Fenofibrate
U202363UOS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-66Informations de copyright
Copyright © 2018. Published by Elsevier B.V.